Roche Holding AG
-
Roche’s Tecentriq wins priority review from US FDA for treating lung cancer
Dec 5, 2018Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has... -
Roche Holding AG to buy Flatiron Health for $1.9 billion
Feb 16, 2018In 2016, Roche led a $175 million investment into Flatiron, in part to help the Swiss company harness the deluge of still-underutilized data collected from cancer patients with the New York City-based company’s products. Swiss drugmaker... -
Roche’s Alecensa halted the spread of lung cancer for longer time than treatment with Pfizer’s Xalkori
Jun 5, 2017News Hour: Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc’s Xalkori with fewer side effects, according to trial results presented on...
